146 related articles for article (PubMed ID: 38216890)
21. Characteristics and Outcomes of Anti-interferon Gamma Antibody-Associated Adult Onset Immunodeficiency.
Zhang B; Fan J; Huang C; Fan H; Chen J; Huang X; Zeng X
J Clin Immunol; 2023 Oct; 43(7):1660-1670. PubMed ID: 37365453
[TBL] [Abstract][Full Text] [Related]
22. Disseminated
Su SS; Zhang SN; Ye JR; Xu LN; Lin PC; Xu HY; Wu Q; Li YP
Infect Drug Resist; 2019; 12():3189-3195. PubMed ID: 31632104
[TBL] [Abstract][Full Text] [Related]
23. Case report: Diagnosis of
Du R; Feng Y; Mao H
Front Cell Infect Microbiol; 2023; 13():1163846. PubMed ID: 37469600
[TBL] [Abstract][Full Text] [Related]
24. Disseminated Mycobacterium simiae infection in a patient with adult-onset immunodeficiency due to anti-interferon-gamma antibodies - a case report.
Keragala BSDP; Gunasekera CN; Yesudian PD; Guruge C; Dissanayaka BS; Liyanagama DP; Jinadasa GIM; Constantine SR; Herath HMMTB
BMC Infect Dis; 2020 Apr; 20(1):258. PubMed ID: 32234012
[TBL] [Abstract][Full Text] [Related]
25. Clinical findings of Talaromyces marneffei infection among patients with anti-interferon-γ immunodeficiency: a prospective cohort study.
Chen ZM; Li ZT; Li SQ; Guan WJ; Qiu Y; Lei ZY; Zhan YQ; Zhou H; Lin S; Wang X; Li Z; Yang F; Zeng W; Lin Y; Liu J; Zhang JQ; Ye F
BMC Infect Dis; 2021 Jun; 21(1):587. PubMed ID: 34144700
[TBL] [Abstract][Full Text] [Related]
26. Incorrect diagnoses in patients with neutralizing anti-interferon-gamma-autoantibodies.
Wu UI; Wang JT; Sheng WH; Sun HY; Cheng A; Hsu LY; Chang SC; Chen YC
Clin Microbiol Infect; 2020 Dec; 26(12):1684.e1-1684.e6. PubMed ID: 32120037
[TBL] [Abstract][Full Text] [Related]
27. Daratumumab (Anti-CD38) for Treatment of Disseminated Nontuberculous Mycobacteria in a Patient With Anti-Interferon-γ Autoantibodies.
Ochoa S; Ding L; Kreuzburg S; Treat J; Holland SM; Zerbe CS
Clin Infect Dis; 2021 Jun; 72(12):2206-2208. PubMed ID: 32745179
[TBL] [Abstract][Full Text] [Related]
28. [DISSEMINATED NONTUBERCULOUS MYCOBACTERIOSIS THAT IS POSITIVE FOR NEUTRALIZING ANTI-INTERFERON-GAMMA AUTOANTIBODIES: A NEW DISEASE CONCEPT BASED ON HOST FACTORS].
Sakagami T
Kekkaku; 2015 Jun; 90(6):561-4. PubMed ID: 26489159
[TBL] [Abstract][Full Text] [Related]
29. Interferon-γ Autoantibodies as Predisposing Factor for Nontuberculous Mycobacterial Infection.
Valour F; Perpoint T; Sénéchal A; Kong XF; Bustamante J; Ferry T; Chidiac C; Ader F;
Emerg Infect Dis; 2016 Jun; 22(6):1124-1126. PubMed ID: 27192204
[No Abstract] [Full Text] [Related]
30. Disseminated Mycobacterium haemophilum skeletal disease in a patient with interferon-gamma deficiency.
Otome O; O'Reilly M; Lim L
Intern Med J; 2015 Oct; 45(10):1073-6. PubMed ID: 26429217
[TBL] [Abstract][Full Text] [Related]
31. Pathogen spectrum and immunotherapy in patients with anti-IFN-γ autoantibodies: A multicenter retrospective study and systematic review.
Qiu Y; Fang G; Ye F; Zeng W; Tang M; Wei X; Yang J; Li Z; Zhang J
Front Immunol; 2022; 13():1051673. PubMed ID: 36569827
[TBL] [Abstract][Full Text] [Related]
32. Disseminated cutaneous Mycobacterium kansasii infection presenting with Rosai-Dorfman disease-like histological features in a patient carrying anti-interferon-γ autoantibodies.
King YA; Hu CH; Lee YJ; Lin CF; Liu D; Wang KH
J Dermatol; 2017 Dec; 44(12):1396-1400. PubMed ID: 28836691
[TBL] [Abstract][Full Text] [Related]
33. Patient ethnicity and causative species determine the manifestations of anti-interferon-gamma autoantibody-associated nontuberculous mycobacterial disease: a review.
Hase I; Morimoto K; Sakagami T; Ishii Y; van Ingen J
Diagn Microbiol Infect Dis; 2017 Aug; 88(4):308-315. PubMed ID: 28633901
[TBL] [Abstract][Full Text] [Related]
34. Anti-IFN-γ autoantibodies underlie disseminated Talaromyces marneffei infections.
Guo J; Ning XQ; Ding JY; Zheng YQ; Shi NN; Wu FY; Lin YK; Shih HP; Ting HT; Liang G; Lu XC; Kong JL; Wang K; Lu YB; Fu YJ; Hu R; Li TM; Pan KS; Li XY; Huang CY; Lo YF; Chang IY; Yeh CF; Tu KH; Tsai YH; Ku CL; Cao CW
J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32880631
[TBL] [Abstract][Full Text] [Related]
35. The role of interferon-gamma and interferon-gamma receptor in tuberculosis and nontuberculous mycobacterial infections.
Ghanavi J; Farnia P; Farnia P; Velayati AA
Int J Mycobacteriol; 2021; 10(4):349-357. PubMed ID: 34916451
[TBL] [Abstract][Full Text] [Related]
36. Recurrent disseminated
Zeitler K; Walter J; Khan F; Sriaroon C
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33509870
[TBL] [Abstract][Full Text] [Related]
37. Novel assay to detect increased level of neutralizing anti-interferon gamma autoantibodies in non-tuberculous mycobacterial patients.
Shima K; Sakagami T; Tanabe Y; Aoki N; Moro H; Koya T; Kagamu H; Hasegawa T; Suzuki E; Narita I
J Infect Chemother; 2014 Jan; 20(1):52-6. PubMed ID: 24462426
[TBL] [Abstract][Full Text] [Related]
38. Case report: Drug rash with eosinophilia and systemic symptoms syndrome in a patient with anti-interferon-γ autoantibody-associated immunodeficiency.
Nie Y; Wang H; Dong X; Pan S; Zhang T; Ran J; Zhang Y; Fan J; Zhang L; Wang J
Front Immunol; 2022; 13():969912. PubMed ID: 36072590
[TBL] [Abstract][Full Text] [Related]
39. Functional neutralization of anti-IFN-γ autoantibody in patients with nontuberculous mycobacteria infection.
Krisnawati DI; Liu YC; Lee YJ; Wang YT; Chen CL; Tseng PC; Lin CF
Sci Rep; 2019 Apr; 9(1):5682. PubMed ID: 30952894
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome and laboratory markers for predicting disease activity in patients with disseminated opportunistic infections associated with anti-interferon-γ autoantibodies.
Angkasekwinai N; Suputtamongkol Y; Phoompoung P; Pithukpakorn M; Wongswat E; Umrod P; Tongsai S; Foongladda S
PLoS One; 2019; 14(4):e0215581. PubMed ID: 31022229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
